XXXX after cardiac surgery: results of @entity7306 therapy.

@entity1 @entity1165 @entity551 @entity956 @entity7306 @entity955 @entity4710 @entity943 @entity2798
Of 1,247 consecutive @entity1 who underwent cardiac surgery, 297 (24%) developed a post-operative @entity4710 . Of these @entity1 , 201 were suitable for treatment according to the study protocol. All @entity1 were initially given digoxin 0.75 mg intravenously (i.v.). After two hours, those 156 @entity1 whose @entity943 persisted were given a 2 mg/kg loading dose of @entity7306 (i.v.), followed by a constant i.v. infusion (0.4 mg kg-1 h-1) or oral therapy (600 mg daily). Within a further 12 hours, 75 @entity1 (48%) reverted to sinus rhythm, 24 within one hour. Thus 120/201 @entity1 (60%) reverted to sinus rhythm within 14 hours of commencing therapy. Reversion rates of those @entity1 with both @entity955 and flutter (AF/AFL) were significantly lower than those with AF (p less than 0.001) or AFL (p less than 0.02) alone. A further 70 @entity1 reverted to sinus rhythm in one to 13 (mean four) days on continued drug therapy. @entity2798 restored sinus rhythm in six subjects. @entity943 persisted in five @entity1 (2.5%) at hospital discharge. Side-effects of @entity7306 were noted in 19% of @entity1 . Urinary retention was common (11.5%). Four @entity1 with @entity956 developed 1:1 atrioventricular conduction with the @entity7306 loading dose. One @entity1 with @entity955 developed @entity1165 during injection of the loading dose of @entity7306 , but was successfully cardioverted to sinus rhythm. Two further @entity1 developed significant @entity551 (less than 90 mmHg systolic). @entity7306 is effective in the treatment of post-operative @entity4710 , but its routine use in this situation may be associated with an unacceptably high incidence of side-effects.
